Karl H. Beyer

from Wikipedia, the free encyclopedia

Karl Henry Beyer Jr. (* 1914 in Henderson (Kentucky) ; † December 2, 1996 in Norristown (Pennsylvania) ) was an American pharmacologist .

He was with Merck Sharp & Dohme (MSD) for three decades , most recently as Vice President for Research, and was Professor at the Hershey Medical Center at Pennsylvania State University for 23 years . He has also taught at Vanderbilt University and Temple University.

Beyer graduated from Western Kentucky State College with a bachelor's degree in 1935 and received his doctorate in medicine and physiology from the University of Wisconsin . In 1942 he joined MSD's predecessor company in West Point, Pennsylvania, which merged with Merck in 1953.

Beyer developed the uricosuric probenecid (at MSD Benemid), one of the first effective drugs in the treatment of gout. He also developed one of the first diuretics , chlorothiazide (called Diuril by MSD). It was one of the first effective medicines for high blood pressure with relatively few side effects. He held more than 20 patents.

In 1973 he retired from MSD and began his academic career.

He was Scholar in Residence at the Fogarty International Center of the National Institutes of Health.

Beyer was President of the American Society for Pharmacology and Experimental Therapeutics and President of the Federation of American Societies for Experimental Biology.

In 1964 he received the Canada Gairdner International Award . He and his team received the Lasker Foundation's Special Public Health Award in 1975 for the development of chlorothiazide. He also received the Sollmann Award. In 1979 Beyer was elected to the National Academy of Sciences , and in 2019 was posthumously inducted into the National Inventors Hall of Fame .

Fonts

  • The discovery, development and delivery of drugs, SP Medical and Scientific Books 1978

Web links

Individual evidence

  1. ^ Lasker Awards